Evidence map›Paper›PMID 31908418›Full record

Trial reportDrug design, development and therapy2019

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study.

Liming Wang, Shigao Huang, Shimei Li, Ming Li, Jun Shi, Wen Bai, Qianyun Wang, Libo Zheng, Yongjun Liu

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05003934 (Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Rheumatoid Arthritis), which is not on this map. Cited by 98 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05003934 phase1recruitingnot on this mapstarted 2021, after this paper: background citation

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Rheumatoid Arthritis

TypeinterventionalSponsorThe Foundation for Orthopaedics and Regenerative MedicineRan2021 to 2026Enrolled20ConditionsRheumatoid ArthritisArmsAlloRx
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liming Wang *Cell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Shigao Huang *Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, People's Republic of China.ORCID 0000-0001-7365-4441
Shimei LiCell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Ming LiCell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Jun ShiCell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Wen BaiCell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Qianyun WangCell Therapy Center, 986 Hospital of People's Liberation Army Air Force, Xi'an, Shaanxi, People's Republic of China.
Libo ZhengStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, People's Republic of China.
Yongjun LiuStem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe traditional anti-inflammation disease-modifying anti-rheumatic drugs (DMARDs) have limited therapeutic effects in rheumatoid arthritis (RA) patients. We previously reported the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSC) treatment in RA patients that were observed for up to 8 months after UC-MSC infusion. The aim of this study is to assess the long-term efficacy and safety of UC-MSC along with DMARDs for the treatment of RA.

methods64 RA patients aged 18-64 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 × 10

results1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RF of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment (P < 0.05).

conclusionUC-MSC cells plus DMARDs therapy can be a safe, effective and feasible therapeutic option for RA patients.

Indexed as

Mesenchymal Stem Cell TransplantationAdolescentAdultArthritis, RheumatoidFemaleHumansInjections, IntravenousMaleMesenchymal Stem CellsMiddle AgedProspective StudiesUmbilical CordYoung Adultcell therapyrheumatoid arthritisumbilical cord mesenchymal stem cell

Identifiers

PMID31908418
PMCPMC6930836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.